Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 mRNA dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Antwerp University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
WT1 mRNA dendritic cell vaccine is an autologous cellular immunotherapy developed by Antwerp University Hospital (UZA) for the treatment of hematological malignancies, primarily acute myeloid leukemia (AML). The vaccine is produced by differentiating a patient's peripheral blood monocytes into dendritic cells (DCs) ex vivo. These DCs are then matured and transfected via electroporation with messenger RNA (mRNA) encoding the Wilms' Tumor 1 (WT1) protein, a zinc-finger transcription factor that is highly overexpressed in AML and other cancers. Upon intradermal administration, the transfected DCs present WT1-derived peptides on their surface, which primes and activates the patient's own T cells to recognize and eliminate residual WT1-expressing leukemic cells. This approach is primarily investigated as a post-remission strategy to prevent relapse in high-risk patients.
- Other names
- WT1 mRNA-electroporated dendritic cell vaccineWT-1 mRNA-electroporated dendritic cell vaccineWT 1 mRNA-electroporated dendritic cell vaccineWT1 mRNA DC vaccineWT-1 mRNA DC vaccineWT 1 mRNA DC vaccineautologous WT1 mRNA-electroporated dendritic cell vaccine
02
Targets
WT1-pMHC (Wilms tumor 1–derived peptide–MHC class I complex)pMHC-II (Peptide-major histocompatibility complex class II complex)IL-15Rβγ (Interleukin-15 receptor subunit beta/common gamma chain complex)
Beyond the preview
Go deeper on WT1 mRNA dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 mRNA dendritic cell vaccine.